1	Non-Adherence Tree Analysis (NATA) - an adherence improvement framework: a COVID-19 case
2	study
3	
4	
5	Ernest Edifor <sup>1*</sup> , Regina Brown <sup>2</sup> , Paul Smith <sup>3</sup> , Rick Kossik <sup>4</sup>
6	
7 8	<sup>1</sup> Operations, Technology, Events and Hospitality Management, Manchester Metropolitan University, Manchester, Lancashire, UK
9	<sup>2</sup> Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
10	<sup>3</sup> Marketing, Retail and Tourism, Manchester Metropolitan University, Manchester, Lancashire, UK
11	<sup>4</sup> Research and Development, GoldSim Technology Group LLC, Seattle, Washington, USA
12	
13	*Corresponding author
14	Email: e.edifor@mmu.ac.uk (EE)
15	
16	
17	

# 18 Abstract

19	Poor adherence to medication is a global phenomenon that has received a significant amount of
20	research attention yet remains largely unsolved. Medication non-adherence can blur drug efficacy
21	results in clinical trials, lead to substantial financial losses, increase the risk of relapse and
22	hospitalisation, or lead to death. The most common methods measuring adherence are post-treatment
23	measures; that is, adherence is usually measured after the treatment has begun. What the authors are
24	proposing in this multidisciplinary study is a technique for analysing the factors that can cause non-
25	adherence before or during medication treatment.
26	Fault Tree Analysis (FTA), allows system analysts to determine how combinations of simple faults of
27	a system can propagate to cause a total system failure. Monte Carlo simulation is a mathematical
28	algorithm that depends heavily on repeated random sampling to predict the behaviour of a system. In
29	this study, the authors propose the use of Non-Adherence Tree Analysis (NATA), based on the FTA
30	and Monte Carlo simulation techniques, to improve adherence. Firstly, the non-adherence factors of a
31	medication treatment lifecycle are translated into what is referred to as a Non-Adherence Tree (NAT).
32	Secondly, the NAT is coded into a format that is translated into the GoldSim software for performing
33	dynamic system modelling and analysis using Monte Carlo. Finally, the GoldSim model is simulated
34	and analysed to predict the behaviour of the NAT.
35	This study produces a framework for improving adherence by analysing social and non-social
36	adherence barriers. The results reveal that the biggest factor that could contribute to non-adherence to
37	a COVID-19 treatment is a therapy-related factor (the side effects of the medication). This is closely
38	followed by a condition-related factor (asymptomatic nature of the disease) then patient-related
39	factors (forgetfulness and other causes). With this information, clinicians can implement relevant
40	measures and allocate resources appropriately to minimise non-adherence.
41	

42 Keywords: non-adherence, fault tree analysis, Monte Carlo simulation, COVID-19

# 43 Introduction

44 A great proportion of patients (especially those with chronic diseases) are non-adherent to their 45 medication regimen [1,2]. This has led many researchers to the conclusion that non-adherence poses a 46 significant challenge in medical practice [3,4]. Some authors [5] class non-adherence as an 47 "epidemic", while the World Health Organisation (WHO) [1] considers it as "a worldwide problem 48 with striking magnitude". Patients' non-adherence to treatment interventions could have grave 49 consequences; it could blur the efficacy of treatments [6], create large financial costs to sponsors [7], 50 cause adverse events or even lead to death in some cases [8]. 51 Non-adherence to medications is not limited to any particular disease – acute or chronic; it affects all 52 diseases [9] and can be influenced by the timing, consistency and persistence of taking medications. 53 Barriers to medication adherence can vary significantly, ranging from patient-related barriers to 54 treatment-related barriers. Care providers, the healthcare system and medical staff also contribute to 55 non-adherence [4,10]. Given this variation in barriers to adherence, there is no single intervention that 56 will effectively minimise medication non-adherence [4,11]. For example, behavioural modification is 57 one way to improve adherence however, this is a very challenging solution to implement as human 58 behaviour is not easily altered. Behavioural modification can take the forms of education, motivation, 59 support and monitoring [12]. Tackling individual aspects of non-adherence can be done, however, 60 there is a need for a multidisciplinary approach to medication non-adherence [12]. 61 There are various techniques for assessing non-adherence. Though some are classic, such as pill 62 counting, others employ more sophisticated approaches [13]. Methods for measuring medication 63 adherence can be generally put in two main categories: direct and indirect [3]. The former provides 64 proof that patients have taken their medication as prescribed while the latter cannot provide such 65 proof. Direct methods include body fluid sampling, direct observation of patient and measurement of 66 biological markers [6]. Indirect methods, which are more widely implemented, include pill count, 67 patient questionnaire [14], self-report forms, and electronic monitoring devices. Medication adherence 68 is characterised by three main components: initiation (the point when the patient takes the first dose as

69	prescribed), implementation (period of dosing regimen complying with prescription) and
70	discontinuation (the point when the patient stops taking medication as prescribed) [15].
71	Measuring medication adherence can be challenging due to the use of adherence measures that have
72	poor accuracy and reliability [16]. Most of the methods for measuring adherence are performed during
73	the implementation phase of adherence [3]. Sometimes adherence measurements are performed
74	during the discontinuation phase [17]. There is limited literature on the methods for measuring
75	adherence before the initiation phase. Self-report methods of measuring adherence are usually
76	performed during the implementation phase. However, these self-reporting tools can be used as
77	historical data to measure adherence before the initiation phase of other future treatments. The
78	Medication Adherence Reasons Scale (MAR-Scale) and the Morisky Medication Adherence Scale
79	(MMAS) can be used to measure adherence before the initiation stage [18,19]. Knowing the common
80	reasons for a patient's non-adherence to medications that they take for their chronic medical
81	conditions can help clinicians or pharmacists design interventions that will increase the chances of the
82	patient adhering to the new medication before the patient starting the medication. The MMAS scale
83	requires the patient to have other chronic medical conditions for which they are taking medications.
84	The MAR-Scale is unable to fully capture and analyse system conditions that may contribute to non-
85	adherence but may not be directly associated with the patient or the medication.
86	Various techniques proposed for improving adherence are complex and ineffective, therefore, they are
87	unable to realise the full benefits a treatment could deliver [16]. It is rational to assess and measure
88	patients' likely non-adherence before the initiation stage of medication treatment to improve
89	adherence. The authors employ a proven probabilistic risk assessment technique to estimate the
90	likelihood of non-adherence before the initiation stage. The results of this study help clinicians to
91	identify and assess barriers to adherence; this aids them in the development of non-adherence
92	mitigating strategies and allocation of resources to improve adherence before the initiation stage of
93	medication adherence.

# 94 Method

# 95 Fault Tree Analysis (FTA)

96 Fault Tree Analysis (FTA) [20], since its inception, has been used mostly in the engineering sector. It 97 is a tree-like graphical representation of how basic components failures (basic events) of a system can 98 propagate to cause a total system failure (top-event). Events are logically connected using the Boolean 99 gates AND, OR and sometimes the Priority-AND (PAND) gates – depicted in Fig 1. The AND gate 100 (conjunction) represents the situation where all children events of an output event need to occur for 101 the output event to occur. The OR (disjunction) gate represents the situation where at least one child 102 event of an output event need to occur to trigger the occurrence of the output event. The Priority-AND 103 (PAND) gate represents the scenario where all the children events of an output event occur in a strict 104 sequence – one after another – for the output event to occur.

## 105 Fig 1. FTA Logic Gates

106 In Fig 1X, the output event Q is triggered when its input (or child) events A and B have occurred

107 within a given time, t. In Fig 1Y, the output event Q is triggered after a given time, t, when at least

108 one of its input events -A or B - have occurred. Fig 1Z depicts the PAND gate where the output

109 event Q is triggered after a given time t only when its input events A occurs before B. For a detailed

110 description of how FTA is performed, the reader is referred to Vesely et al. [20]. In a logical

111 expression, the AND, OR and PAND gates are represented by the symbols, \*, + and < respectively.

112 Once a system has been translated into a fault tree, it can be analysed logically (qualitatively). The

113 logical analysis involves the determination of minimal cut sets (MCS) using Boolean algebra. MCS is

114 the smallest combination of basic events that are *necessary* and *sufficient* to cause the top event.

115 Necessary means each basic event in the MCS is needed for the top event to occur and sufficient

- 116 means the MCS does not need the occurrence of additional events to cause the top event occurrence.
- 117 In addition to creating MCS, the logical analysis also reveals single points of failure of a system and
- 118 reveals relationships between components. Quantitative analysis or probabilistic analysis involves the

evaluation of the probability of the system failing using the MCSs. The probability, *P*, of the PAND,

120 AND and OR (in order of precedence), within a given time t, for an events  $X_1...X_n$  can be calculated

- 121 using Equations (1), (2) and (3) respectively [20]. Equation (1) is limited to exponentially distributed
- 122 independent events.

$$P\{X_n < X_{n-1} < \dots < X_2 < X_1\}(t) = \prod_{i=1}^n \lambda_i \sum_{k=0}^n \left[ \frac{e^{(a_k t)}}{\prod_{\substack{j=0\\j \neq k}}^n (a_k - a_j)} \right]$$
(1)

124 Where  $a_0 = 0$  and  $a_m = -\sum_{j=1}^m \lambda_i$  for m > 0.

$$P\{X_1 * X_2 * \dots * X_{n-1} * X_n\}(t) = \prod_{i=1}^n P\{X_i\}(t)$$

125

123

$$P\{X_1 + X_2 + \dots + X_{n-1} + X_n\}(t) = 1 - \left\{\prod_{i=1}^n (1 - P\{X_i\}(t))\right\}$$

126

To improve the overall reliability of the system, one could perform criticality/sensitivity analysis [20] to determine how individual components contribute to the system failure. The results of a sensitivity analysis enable investigators to implement mitigating strategies, know the quality of components to use and allocate resources appropriately to improve the overall reliability of the system.

## 131 GoldSim Software

Most traditional FTA-based techniques have some limitations; they are mostly limited to analytical approaches with exponentially distributed component failures, they cannot capture repairable events and they are unable to process other system environment data, such as the time of operation. To evaluate real-world scenarios, one needs to overcome such limitations because real-world events are dynamic, mostly repairable, and could have different failure distributions. These limitations are

- 137 addressed by GoldSim software [21]. GoldSim is a software capable of performing the modelling and
- 138 probabilistic analysis of complex real-world systems using Monte Carlo simulation. It has features for
- 139 representing the classical Boolean gates AND and OR. The PAND gate can be modelled accurately
- 140 using dynamic and intuitive elements in GoldSim.

(2)

(3)

# 141 Non-Adherence Tree Analysis (NATA)

142	The authors propose the Non-Adherence Tree Analysis (NATA) – a systematic and holistic technique
143	heavily based on the fault tree analysis technique. Unlike FTA where the primary focus of the
144	investigation is the reliability of a system using failure data (such as failure rate), the primary focus on
145	the investigation in NATA is non-adherence (or discontinuation of medication) using factors that
146	trigger non-adherence. NATA follows the guidelines of the classical FTA, however, new terms are
147	defined in this study to reflect its novel domain of application; these terms have been adapted from
148	classical FTA definitions [20]. Examples will be based on this scenario: in a study, 20 patients (out of
149	100 patients) fail to take their medication as prescribed during a 10-day medication regimen. Out of
150	the 20 non-adherent patients, 6 were non-adherent due to forgetfulness (FORG), 4 due to side effects
151	(SIDE) and 10 due to other factors (OTHER).
152	Days of Medication Adherence (DoM): This is the total number of days a medication
153	should be taken in a treatment regimen for a given study.
154	Number of participants (NoP): This is the total number of participants in a study.
155	Non-Adherence (NA): This is known as the top event in classical FTA. NA represents the
156	situation where a prescription to a medication regimen has not been followed as instructed.
157	Meaning, NA is discontinuation in adherence to the medication before the end of prescribing
158	period [15].
159	Non-adherence tree (NAT): A graphical top-down deductive structure that represents the
160	non-adherence factors as nodes with Boolean logic gates connecting these nodes to show the
161	relationship between them. Fig 2 is a simple NAT for the scenario. When creating NATs,
162	additional information such as the time of operation, replacements, repair/resolution, etc., can
163	be included in the rectangle of the corresponding non-adherence factor.
164	Fig 2. A Non-Adherence Tree (NAT)

167 true when the factor has occurred and false otherwise. This could be *FORG*, *SIDE* or *OTHER*.

- 168 **Basic NAF**: This is synonymous to a basic event in FTA. It is a discrete NAF that cannot be
- 169 decomposed into other NAF. This is *FORG* and *SIDE*; *OTHER* could be broken into other
- 170 NAFs if need be.

171 Non-Adherence Count (NAC): This is the cumulative number of patients who are non-

- adherent in a study, clinical trial or medication administration process. This is calculated as
- 173 the sum of the count of all the occurrences of NAFs. This can be expressed as:

$$NAC = \sum_{i=1}^{n} Count(NAF_i)$$

174 From the scenario,

$$NAC = Count(FORG) + Count(SIDE) + Count(OTHER) = 6 + 4 + 10 = 20$$

175 NAC could also be expressed in terms of the number of days elapsed using NACX, where X is

176 the number of days. For example, NAC3 = 8, means 8 participants were non-adherent by Day

177 3 (counting from Day 1) of a medication regimen.

GrandNoP: this represents the total number of non-adherent patients from *n* different studiesand it can be evaluated as:

$$GrandNoP = \sum_{i=1}^{n} NoP_i$$

180 Non-Adherent Rate per Study (NARS): This is the number of occurrences of a particular

181 NAF per the NoP and can be defined as:

$$NARS = \frac{NAF}{NoP}$$

182 Therefore, the NARS for *FORG* can be evaluated as

$$NARS_{FORG} = \frac{6}{100} = 0.06$$

#### 183 Non-Adherent Rate (NAR): This is synonymous to failure rate or hazard function in FTA.

184 NAR is the rate of occurrences (NAR) per the duration of the medication regimen – usually

185 expressed in days. NAR can be expressed as,

$$NAR = \frac{NARS}{DoM}$$

186 Therefore, the NAR for *FORG* can be evaluated as

$$NAR_{FORG} = \frac{0.06}{10} = 0.006$$

187 Weighted NAR (WNAR): where NARs are to be sourced from multiple studies, it is useful
188 to have a weighted NAR. The WNAR for a particular NAF from *n* studies can be evaluated
189 as:

$$WNAR_{NAF} = \sum_{i=1}^{n} \frac{NAR_{NAF(i)} * NoP_i}{GrandNoP}$$

190 Non-Adherence Factor Probability: This is the probability that a particular NAF will occur

191 and it is represented by P(NAF). The determination of the P(NAF) is based on the probability

distribution of the NAF. For example, given a duration (*d*) of 1 and 10 days respectively, if

193 *FORG* is exponentially distributed, P(*FORG*) can be evaluated as:

$$P(FORG_{NAC1}) = 1 - e^{-(NAR*d)} = 1 - e^{-(0.006*1)} = 0.005982$$

$$P(FORG_{NAC10}) = 1 - e^{-(NAR*d)} = 1 - e^{-(0.006*10)} = 0.058235$$

194 Non-Adherence Probability: This is the overall non-adherence probability – the probability

195 that there will be discontinuation as a result of NAFs at the end of a medication regimen.

197 Therefore, from the scenario, given a duration (*d*) of 10 days, P(NA) is

$$P(NA) = 1 - (1 - P(FORG)) * (1 - P(SIDE)) * (1 - P(OTHER)) = 0.18127$$

# 198 **Results**

- 199 To demonstrate the usefulness of NATA, it is applied to a COVID-19 treatment intervention clinical
- trial. Several clinical trials of drugs targeting COVID-19 have been registered in China [22].
- 201 Remdesivir, a nucleotide analogue, and chloroquine, an anti-malarial compound, have both shown
- 202 inhibition of the new coronavirus [23]. As of April 2020, several clinical trials are testing the
- 203 therapeutic efficacy of remdesivir and hydroxychloroquine (ClinicalTrials.gov: NCT04280705,
- 204 NCT04329923) for COVID-19 treatment. If any of these drugs are shown to be safe and efficacious,
- they could become the first drug approved for the treatment of COVID-19. In a hospitalized setting,
- 206 "there is less consideration given to adherence" [24] therefore, this study will only consider the out-
- 207 patient settings. It is assumed that the treatment for out-patients, who usually have mild symptoms, is
- a tablet that will be administered for 10 days by the patients themselves one pill per day for a study
- 209 population of 1000 patients. The diagram in Fig 3 is a NAT for a hypothetical treatment intervention

210 for COVID-19 using the WHO's dimensions [1,5] and NAFs from six studies [25–30].

### 211 Fig 3. A NAT for COVID-19 Intervention.

212 In Fig 3, non-adherence has been classified into the 5 WHO dimensions: Social/Economic-related

213 factors (SocRel), Patient-related factors (PatRel), Condition-related factors (ConRel), Healthcare-

214 related factors (*HeaRel*) and Therapy-related factors (*TheRel*). These top-level NAFs have sub-NAFs

that are based on factors for non-adherence of oseltamivir, an oral antiviral medication that inhibits

216 influenza viral replication. This antiviral medication is chosen because of the similarities in symptoms

217 between influenza infection and COVID-19. Six studies (covering different demographics and

218 geographic locations) have been used in the determination of these sub-NAFs; they are henceforth

219 referred to as *Study 1* [25], *Study 2* [26], *Study 3* [27], *Study 4* [28], *Study 5* [29] and *Study 6* [30].

220 In general, there is a strong correlation between family/social support networks for patients and their

adherence to a medication regimen [31]. Patients with COVID-19 require self-isolation to avoid the

- spread of the disease. Therefore, limited social support (SocSup) and limited healthcare access
- 223 (HeaAcc) have been considered as NAFs contributing to SocRel. Since this intervention is novel, it is

224	assumed that a NAF in the <i>HeaRel</i> category is "lack of prior knowledge of adhered assumed that a NAF in the <i>HeaRel</i> category is "lack of prior knowledge of adhered assumed that a new second	rence" ( <i>PriKno</i> ) [1.5]

- in addition to limited tablets (*NoTab*) and clinical improvement (*ClinImp*). The medicine delivery
- system in the hospital can also contribute to *HeaRel* if both the ICT (*IctSys*) and manual (*ManSys*)
- 227 delivery systems fail. NAFs contributing to PatRel include patients' forgetfulness (Forgot), choice of
- 228 not taking the medication (NoMed) and other patient-related factors (Other). ConRel and TheRel have
- 229 only one NAF each no symptoms (*NoSym*) and side effects (*SidEff*) respectively.

## 230 Logical Analysis

231 Using basic Boolean logic, the MCS for non-adherence can be evaluated as:

233 = (SocSup + HeaAcc) + (NoMed + Forgot + Other) + NoSys + (ClinImp + NoTab +

$$= SocSup + HeaAcc + NoMed + Forgot + Other + NoSys + ClinImp + NoTab +$$

The MCS reveals that there are ten single points of failure in the system. Both *IctSys* and *ManSys* need to occur together to trigger discontinuation therefore they are not considered single points of failure. With a quick scan at these single points of failure, investigators can determine which aspect of the system need backups. For example, *NoTab* is a factor that could be easily and quickly improved to enhance adherence; not all the other factors can be quickly improved. For a detailed analysis on which factor contributes most to non-adherence, probabilistic analysis is required. Probabilistic analysis can only occur when NARs have been determined.

## 244 Non-Adherence Rates (NARs)

245 It is assumed that the recruited ambulatory participants would fail to adhere to their medication due to

246 HeaAcc resulting in a WNAR of 1.2E-4/day. It is also assumed that PriKno [1,5], has an initial

- 247 WNAR of 1.5E-4. This rate reduces by 8 per cent of the initial WNAR multiplied by the number of
- 248 elapsed day to represent the increasing knowledge of adherence by the medical team. The IctSys and

249	ManSys sub-systems responsible for ordering and dispensing the medicine fail at daily rates of 8.12E-
250	5 and 5.34E-5 with mean-delay-time-until-repair of 4 hours and 2 hours respectively. There is a 2-day
251	delay time until the medication is delivered in case of NoTab. From results presented in Belmaker et
252	al. [25], it is estimated that the WNAR (per day) for SocSup for patients taking oseltamivir who are
253	under age 25, between ages 25 and 45 inclusive and over age 45 are 4.138E-4, 1.379E-4, and 2.069E-
254	4 respectively. Table 1 is a summary of NAFs, NARSs, NARs and WNARs from the six studies [25-
255	30].

Study (S)	NoTabs	SidEff	NoMed	ClinImp	Forgot	NoSym	Other
S1 (NoP=201, DoM=10)	5	3	4	-	-	-	13
NARS	2.488E-02	1.493E-02	1.990E-02	-	-	-	6.468E-02
NAR (per day)	2.488E-03	1.493E-03	1.990E-03	-	-	-	6.468E-03
S2 (NoP=33, DoM=5)	-	1	-	1	-	-	4
NARS	-	3.030E-02	-	3.030E-02	-	-	1.212E-01
NAR (per day)	-	6.061E-03	-	6.061E-03	-	-	2.424E-02
S3 (NoP=331, DoM=6)	-	9	-	-	21	-	7
NARS	-	2.719E-02	-	-	6.344E-02	-	2.115E-02
NAR (per day)	-	4.532E-03	-	-	1.057E-02	-	3.525E-03
S4 (NoP=313, DoM=7)	-	20	-	-	-	42	16
NARS	-	6.390E-02	-	-	-	1.342E-01	5.112E-02
NAR (per day)	-	9.128E-03	-	-	-	1.917E-02	7.303E-03
S5 (NoP=326, DoM=5)	-	24	-	-	7	13	4
NARS	-	7.362E-02	-	-	2.147E-02	3.988E-02	1.227E-02
NAR (per day)	-	1.472E-02	-	-	4.294E-03	7.975E-03	2.454E-03
S6 (NoP=246, DoM=10)	-	24	1	-	22	-	9
NARS	-	9.756E-02	4.065E-03	-	8.943E-02	-	3.659E-02
NAR (per day)	-	9.756E-03	4.065E-04	-	8.943E-03	-	3.659E-03
WNAR	3.448E-04	8.315E-03	3.448E-04	1.379E-04	4.897E-03	5.931E-03	5.002E-03

## 256 Table 1. NAFs, NARSs, NARs and WNARs from six studies

257

# 258 **Probabilistic Analysis**

A GoldSim model was created from the NAT in Fig 3 using the data in Table 1. The system was

simulated over 10 days with a time-step of one hour. For each time-step, 1000 iterations were

261 performed to simulate the behaviour of each participant. Fig 4 is a graph depicting the mean P(NA)

202 and the NAC over ten days. P(NA) on Day U is zero, nowever, as the days progress towards
--

approaches 1; on Day 10, it reaches 0.22 with a 5% and 95% confidence bounds of 0.2 and 0.25

- respectively and a standard deviation of 0.42. Missing at least one pill (of the 10 pills) results in non-
- adherence. The results predict that 776 participants would take all their medications (10 pills) as
- 266 prescribed in ten days; 224 participants would miss at least one pill. This result aligns with the results
- 267 of the six studies: adherence to such treatment is very high. The NAF contributing the most to P(NA)
- 268 is the *PatRel*. Meaning, patient-related factors are strongly correlated to non-adherence.

## 269 Fig 4. Probability of Non-Adherence and Non-Adherent Participants

Cumulatively over the 10 days, the average number of patients who would be non-adherent increases
steadily. By the end of Day 1, it is estimated that 21 would miss their pills. From Day 1 to the end of
Day 5, it is estimated that 105 participants would miss at least one pill. At the end of the medication
regimen, it is estimated that 224 patients would miss at least one of their pills. However, the number

of new daily cases on non-adherence had no clear pattern; there were no new cases on some days

275 whiles only 2 new cases of non-adherence would be observed on Day 10. The average NAC to NoP

- ratio in the six studies is 0.17; the NAC to NoP ratio for the COVID-19 case study is 0.22. The
- 277 difference in ratios is due to the additional NAFs (such as SocSup, HeaAcc and PriKno) added to give

a more accurate dynamic of the behaviour of non-adherence to the COVID-19 disease.

# 279 **Discussion**

280 Based on the NATA results for the case study, a COVID-19 treatment is likely to have the non-

adherence probability predicted in Fig 4. Given the high rate of contagiousness, significant financial and economic burden, and the number of deaths COVID-19 has caused, there is a need for the result to improve – that is, increase overall adherence rate. At a glance, it seems that patient-related factors contribute the most to non-adherence. However, patient-related factors are not solely responsible for non-adherence; other factors also contribute to non-adherence – this affirms results in previous studies [1]. Further investigation of the results gives us a different picture. In Fig 5, it can be seen that patient-

287 related factors contribute about 40% to the non-adherence probability. However, when the constituent

288 NAFs are considered, *SidEff* is the biggest contributor, closely followed by *Forgot*, *NoSym*, *Other*,

289 etc. This means that clinicians hoping to improve the patients' adherence to a COVID-19 treatment

should concentrate on reducing these factors – more importantly, the *SidEff. NoSym* is known to have

a relatively high ratio in known COVID-19 cases [32].

### 292 Fig 5. Contribution of NAFs to NA

293 This study has established that NATA can reveal the non-adherence factors clinicians need to know to

allocate resources targeting those non-adherence factors. It is assumed that, given the information

295 produced by NATA, clinicians decide to reduce Forgot, Other, NoSym and SidEff by 20% each

through measures such as using a pillbox, software app, information/education [33], trust in physician

[34] and psychological ownership [35]. The GoldSim model was updated and re-run to determine the

impact of the changes on non-adherence; the results are displayed in Fig 6. As expected, the overall

non-adherence of the improved system has reduced by nearly 4% at a mean of 0.187, 5% and 95%

300 confident intervals of 0.17 and 0.21 respectively and a standard deviation of 0.39. This reduced the

301 mean number of tablets wasted from 224 to 187 – saving 37 pills that could potentially increase the

302 evaluation of the efficacy of the treatment by 0.37%.

### 303 Fig 6. Improvement of Contribution of NAFs to NA

304 The significant changes made to the improved model using very generous reduction rates of 20% have

305 enhanced adherence by 3.7% – not as much as one would have expected. The reason for this big

306 change but relatively little impact is that all NAFs would have to be reduced to make significant

307 changes to the overall non-adherence. The results of this case study affirm that no single factor can

308 fully minimise non-adherence [4,11] and provides empirical proof. However, it is still clear that the

309 four main contributing NAFs are SidEff, Forgot, NoSym and Other; these are factors clinicians should

310 seek to improve to minimise non-adherence.

# 311 Contribution of NATA

Adherence measuring techniques are usually implemented when a treatment has already begun. Thisstudy has introduced NATA for predicting patients' adherence behaviour so that measures can be put

314	in place to improve adherence. NATA is not only a pre-treatment technique; it can also be used during
315	treatment. A NATA model in GoldSim can be updated with changes and re-run to determine how the
316	changes affect the system. This study has proven that NATA can identify non-adherence factors of a
317	treatment regimen and their relationships and contribution to overall non-adherence. With such
318	information, clinicians can implement mitigating strategies to minimise the risk of high non-
319	adherence. Most of the data used in this study - extracted from other studies - are occurrence rates,
320	hence it was assumed they were exponentially distributed. However, the proposed solution, NATA
321	and GoldSim, are not restricted to exponentially distributed rates. Using Monte Carlo simulation, the
322	proposed solution can model and analyse any case study.

----

## 323 Limitation

- - - -

324 This study is not without limitations. The data used in the COVID-19 case study are based on a 325 similar drug – oseltamivir – of a similar disease. The authors assume that the behaviour of COVID-19 326 patients would be similar to that of the patients who took oseltamivir from six studies. The six studies 327 from which the data was extracted were diverse in terms of demographics and population; therefore, 328 for a geographically specific application, the data may need to be streamlined. The simulation for the 329 case study was modelled to run for ten consecutive days, which is not an accurate reflection of real-330 world studies where participants of a trial start on different days. NATA is not a stand-alone solution 331 for addressing all the issues with non-adherence; it depends on the results of studies and techniques 332 such as the Medication Adherence Reasons Scale or the Morisky Medication Adherence Scale 333 (MMAS) for data to perform its analysis. In the future, data for NAFs can be sourced from Big Data 334 and/or Artificial Intelligence-enabled systems where possible.

# 335 Conclusion

336 Non-adherence to a medication regimen is widespread. In addition to financial losses, non-adherence

337 can blur the efficacy of drugs and lead to loss of lives. Most adherence measuring techniques are

implemented after the patient has started the medication regimen. This article has explored the use of

339 Fault Tree Analysis (FTA) – an engineering technique for probabilistic risk analysis – to predict the

15

. . .

- 340 nature of non-adherence. It proposes the Non-Adherence Tree Analysis (NATA) based on classical
- 341 FTA for modelling and analysing a medication regimen. Based on the results NATA produces, health
- 342 professionals and clinicians can implement strategies and allocate resources to help improve
- 343 adherence. NATA can serve as a framework for analysing non-adherence factors in clinical trials and
- 344 other drug administration processes. The authors have applied NATA to a hypothetical COVID-19
- treatment; the results reveal the factors clinicians should concentrate on to minimise non-adherence.

# 346 Acknowledgements

- 347 The authors would like to thank Prof. Peter Naude for reviewing the article and providing constructive
- 348 comments that have contributed immensely to its quality.

# 349 **References**

- 350 [1] De Geest S, Sabaté E. Adherence to long-term therapies: Evidence for action. Eur J
- 351 Cardiovasc Nurs 2003;2:323. https://doi.org/10.1016/S1474-5151(03)00091-4.
- 352 [2] Wiecek E, Tonin FS, Torres-Robles A, Benrimoj SI, Fernandez-Llimos F, Garcia-Cardenas V.
- 353 Temporal effectiveness of interventions to improve medication adherence: A network meta-

354 analysis. PLoS One 2019;14:e0213432. https://doi.org/10.1371/journal.pone.0213432.

- 355 [3] Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–97.
- 356 [4] Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-Reported
- 357 Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis.
- 358 PLOS Med 2016;13:e1002183. https://doi.org/10.1371/journal.pmed.1002183.
- 359 [5] ASA, ASCP. Medication Adherence Where Are We Today □? Overview 2006.
- 360 http://www.adultmeducation.com/overviewofmedicationadherence\_4.html (accessed August
  361 12, 2016).
- 362 [6] Vernon A, Fielding K, Savic R, Dodd L, Nahid P. The importance of adherence in tuberculosis
   363 treatment clinical trials and its relevance in explanatory and pragmatic trials. PLoS Med

- 364 2019;16. https://doi.org/10.1371/journal.pmed.1002884.
- 365 [7] Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic
- 366 impact of medication non-adherence by disease groups: A systematic review. BMJ Open
- 367 2018;8:16982. https://doi.org/10.1136/bmjopen-2017-016982.
- 368 [8] Wu J-R, Moser DK. Medication Adherence Mediates the Relationship Between Heart Failure
- 369 Symptoms and Cardiac Event-Free Survival in Patients With Heart Failure. J Cardiovasc Nurs
- 370 2018;33:40–6. https://doi.org/10.1097/JCN.00000000000427.
- 371 [9] Costa E, Giardini A, Savin M, Menditto E, Lehane E, Laosa O, et al. Interventional tools to
- 372 improve medication adherence: Review of literature. Patient Prefer Adherence 2015;9:1303–
  373 14. https://doi.org/10.2147/PPA.S87551.
- Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc 2011;86:304–14.
  https://doi.org/10.4065/mcp.2010.0575.
- 376 [11] Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence.
  377 Ther Clin Risk Manag 2005;1:189–99. https://doi.org/10.1089/bar.2012.9960.
- Kleinsinger F. The Unmet Challenge of Medication Nonadherence. Perm J 2018;22:18–033.
  https://doi.org/10.7812/TPP/18-033.
- 380 [13] Aldeer M, Javanmard M, Martin RP. A Review of Medication Adherence Monitoring. Appl
  381 Syst Innov 2018;1:1–27. https://doi.org/10.3390/asi1020014.
- [14] Moon SJ, Lee WY, Hwang JS, Hong YP, Morisky DE. Accuracy of a screening tool for
  medication adherence: A systematic review and meta-analysis of the Morisky Medication
  Adherence Scale-8. PLoS One 2017;12. https://doi.org/10.1371/journal.pone.0187139.
- 385 [15] Vrijens B, Geest S De, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new
  386 taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol
- 387 2012;73:691–705. https://doi.org/10.1111/j.1365-2125.2012.04167.x.

- 388 [16] Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al.
- 389 Interventions for enhancing medication adherence. 2014.
- 390 https://doi.org/10.1002/14651858.CD000011.pub4.
- 391 [17] Torres-Robles A, Wiecek E, Cutler R, Drake B, Benrimoj SI, Fernandez-Llimos F, et al. Using
- 392 dispensing data to evaluate adherence implementation rates in community pharmacy. Front
- 393 Pharmacol 2019;10:1–9. https://doi.org/10.3389/fphar.2019.00130.
- 394 [18] Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication
- adherence measure in an outpatient setting. J Clin Hypertens 2008;10:348–54.
- 396 https://doi.org/10.1111/j.1751-7176.2008.07572.x.
- 397 [19] Unni EJ, Sternbach N, Goren A. Using the Medication Adherence Reasons Scale (MAR-
- 398 Scale) to identify the reasons for non-adherence across multiple disease conditions. Patient
- 399
   Prefer Adherence 2019;13:993–1004. https://doi.org/10.2147/PPA.S205359.
- 400 [20] Vesely WE, Stamatelatos M, Dugan JB, Fragola J, Minarick J, Railsback J. Fault Tree
- 401 Handbook with Aerospace Applications. Washington DC: NASA Office of Safety and Mission
  402 Assurance; 2002.
- 403 [21] Goldsim. Goldsim. A Dyn Simul Approach to Reliab Model Risk Assess Using GoldSim
- 404 2020. https://www.goldsim.com/downloads/documents/GoldSim\_Reliability\_and\_PRA.pdf
  405 (accessed December 15, 2018).
- 406 [22] Brüssow H. The Novel Coronavirus A Snapshot of Current Knowledge. Microb Biotechnol
  407 2020:1751-7915.13557. https://doi.org/10.1111/1751-7915.13557.
- 408 [23] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively
- 409 inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–
  410 71. https://doi.org/10.1038/s41422-020-0282-0.
- 411 [24] Kim J, Combs K, Downs J, Tillman F. Medication adherence: The elephant in the room. US
  412 Pharm 2018;43:30–4.

- 413 [25] Belmaker I, Lyandres M, Bilenko N, Dukhan L, Mendelson E, Mandelboim M, et al.
- 414 Adherence with oseltamivir chemoprophylaxis among workers exposed to poultry during
- 415 avian influenza outbreaks in southern Israel. Int J Infect Dis 2009;13:261–5.
- 416 https://doi.org/10.1016/j.ijid.2008.06.037.
- 417 [26] Chishti T, Oakeshott P. Do general practice patients who are prescribed Tamiflu® actually
- 418 take it? Br J Gen Pract 2010;60:535. https://doi.org/10.3399/bjgp10X514891.
- 419 [27] Choo D, Hossain M, Liew P, Chowdhury S, Tan J. Side effects of oseltamivir in end-stage

420 renal failure patients. Nephrol Dial Transplant 2011;26:2339–44.

- 421 https://doi.org/10.1093/ndt/gfq737.
- 422 [28] McVernon J, Mason K, Petrony S, Nathan P, LaMontagne AD, Bentley R, et al.
- 423 Recommendations for and compliance with social restrictions during implementation of school
- 424 closures in the early phase of the influenza A (H1N1) 2009 outbreak in Melbourne, Australia.

425 BMC Infect Dis 2011;11:1–7. https://doi.org/10.1186/1471-2334-11-257.

- 426 [29] Strong M, Burrows J, Stedman E, Redgrave P. Adverse drug effects following oseltamivir
- 427 mass treatment and prophylaxis in a school outbreak of 2009 pandemic influenza a(H1N1) in
- 428 June 2009, Sheffield, United Kingdom. Eurosurveillance 2010;15:1–6.
- 429 https://doi.org/10.2807/ese.15.19.19565-en.
- 430 [30] Wallensten A, Oliver I, Lewis D, Harrison S. Compliance and side effects of prophylactic

431 oseltamivir treatment in a school in South West England. Eurosurveillance 2009;14:1–4.

- 432 https://doi.org/10.2807/ese.14.30.19285-en.
- Gu L, Wu S, Zhao S, Zhou H, Zhang S, Gao M, et al. Association of social support and
  medication adherence in Chinese patients with type 2 diabetes mellitus. Int J Environ Res
- 435 Public Health 2017;14:1522. https://doi.org/10.3390/ijerph14121522.
- 436 [32] Nishiura H, Kobayashi T, Suzuki A, Jung S-M, Hayashi K, Kinoshita R, et al. Estimation of
  437 the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020.

438 https://doi.org/10.1016/j.ijid.2020.03.020.

- 439 [33] Agyepong IA, Ansah E, Gyapong M, Adjei S, Barnish G, Evans D. Strategies to improve
- 440 adherence to recommended chloroquine treatment regimes: A quasi-experiment in the context
- 441 of integrated primary health care delivery in Ghana. Soc Sci Med 2002;55:2215–26.
- 442 https://doi.org/10.1016/S0277-9536(01)00366-5.
- 443 [34] Lee YY, Lin JL. The effects of trust in physician on self-efficacy, adherence and diabetes
- 444 outcomes. Soc Sci Med 2009;68:1060–8. https://doi.org/10.1016/j.socscimed.2008.12.033.
- 445 [35] Mifsud M, Molines M, Cases AS, N'Goala G. It's MY health care program: Enhancing patient
- 446 adherence through psychological ownership. Soc Sci Med 2019;232:307–15.
- 447 https://doi.org/10.1016/j.socscimed.2019.05.015.

















